Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 17/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7623758 | 0.73 | RAF1 (0.39) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4429666 | 0.70 | RAF1 (0.52) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4426603 | 0.68 | MAPK14 (0.53) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12447254 | 0.66 | MAPK14 (0.40) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12514556 | 0.65 | RAF1 (0.44) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL161668 | 0.65 | RAF1 (0.56) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12446819 | 0.64 | RAF1 (0.35) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12447255 | 0.64 | RAF1 (0.36) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL173108 | 0.64 | RAF1 (0.56) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL12520070 | 0.63 | RAF1 (0.50) | RAF1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020103253-A1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION (US) | 2002-08-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103253-A1 | Inhibition of p38 kinase activity by aryl ureas | MAPK1, MAP3K1, MAP3K7 | RAF1 237/4885MAPK14 40/4885MAPK13 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.